Business Wire

MA-VERACODE

Share
Veracode Research Reveals Government Applications at Heightened Risk of Cyber Attack: 59% Have Flaws Left Unfixed for More than a Year

Veracode, a global leader in application risk management, today released research revealing applications developed by public sector organizations have more security debt than those created by the private sector. Security debt, defined for this report as flaws that remain unfixed for longer than a year, exists in 59 percent of applications in the public sector, compared to the overall rate of 42 percent. The research analyzed public sector organizations in more than 25 countries across the globe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529282258/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 2: Security Debt in Public Sector Applications (Graphic: Business Wire)

“Decades of accumulated security debt in unpatched software and poor security configurations, are in the applications that serve our government,” said Chris Eng, Chief Research Officer at Veracode. “Without a systematic and continuous approach to finding and fixing security flaws, the public sector is left dangerously exposed to attacks from hackers.”

Federal government systems are increasingly under cyberattack, as malicious criminals target public sector organizations with more damaging and disruptive techniques. In response, the federal government is enforcing a flurry of initiatives to strengthen cybersecurity, including efforts to reduce risk in the applications that serve the government. In March of 2024, the Cybersecurity and Infrastructure Security Agency (CISA) and the Office of Management and Budget (OMB) released the Secure Software Development Attestation Form to hold providers to the federal government accountable for insecure software.

Veracode researchers found that while slightly fewer public sector organizations (68 percent) have security debt than other industries (71 percent), they tend to accumulate more of it. Only three percent of applications are flaw-free, compared to six percent across other industries. Even more concerning, 40 percent of public sector entities have persistent, high-severity flaws that constitute ‘critical’ security debt, which would put the confidentiality, integrity, and availability of businesses at serious risk if exploited.

“The good news is that most organizations have the capacity to remediate all critical debt, but risk prioritization is key,” said Eng. “Two-thirds of all flaws in public sector organizations are either less than one year old or are not critical in severity. In addition, less than one percent of all flaws constitute critical security debt. By prioritizing that security debt with focused effort, organizations can achieve maximum risk reduction and then move to address non-critical flaws based on their risk tolerance and capabilities.”

According to the report, security debt in the public sector primarily affects first-party code (93 percent), but most of the critical security debt comes from third-party dependencies (55.5 percent). This reinforces the importance of the Open Source Security Software Initiative (OS3I), an inter-agency working group focused on ensuring open-source software is “as safe, secure and sustainable as it is open.” It also emphasizes the need for organizations to focus on both first- and third-party code to effectively reduce security debt.

The analysis further shows security debt in the public sector is primarily concentrated in older, larger applications (22 percent). This is especially true for critical security debt (30 percent), confirming a correlation between application age and the accumulation of security debt. Researchers also compared the security debt profile for different development languages and found that Java and .NET applications stand out as significant sources of debt in the public sector.

“The current state of software security in the public sector reinforces the importance of making secure by design a standard approach for the whole network connected world,” closed Eng. “We applaud CISA’s recent announcement of its Secure by Design Pledge and are proud to be one of the inaugural signatories. Our goal with this research is to further support our government and industry partners in promoting widespread adoption of these principles.”

The full State of Software Security Public Sector 2024 report is available to download on the Veracode website.

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529282258/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye